BIVI BioVie Inc. Stock Quote

BIVI [NASD]

Index	-	P/E	-	EPS (ttm)	-11.72	Insider Own	0.30%	Shs Outstand	13.92M	Perf Week	-20.06%
Market Cap	186.90M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	144.17%	Shs Float	2.53M	Perf Month	-38.68%
Income	-68.80M	PEG	-	EPS next Q	-	Inst Own	1.00%	Short Float	6.48%	Perf Quarter	-55.95%
Sales	-	P/S	-	EPS this Y	-598.00%	Inst Trans	-	Short Ratio	1.65	Perf Half Y	25.02%
Book/sh	0.94	P/B	14.03	EPS next Y	-	ROA	-841.70%	Target Price	-	Perf Year	317.41%
Cash/sh	0.84	P/C	15.71	EPS next 5Y	-	ROE	-	52W Range	3.50 - 46.10	Perf YTD	-23.85%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-71.39%	Beta	1.94
Dividend %	-	Quick Ratio	36.90	Sales past 5Y	-	Gross Margin	-	52W Low	276.86%	ATR	2.07
Employees	2	Current Ratio	36.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	33.12	Volatility	12.57% 12.03%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	-117.10%	Profit Margin	-	Rel Volume	1.22	Prev Close	13.43
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	99.16K	Price	13.19
Recom	2.00	SMA20	-25.60%	SMA50	-47.27%	SMA200	-26.13%	Volume	120,616	Change	-1.79%

Jan-15-21

Initiated

B. Riley Securities

Buy

$47

Mar-11-21 07:00AM	BioVie to Present at 31st Annual Oppenheimer Healthcare Conference GlobeNewswire +8.09%
Mar-09-21 07:00AM	BioVie Commences Patient Screening in Phase 2 Clinical Trial GlobeNewswire +31.42%
Feb-19-21 07:00AM	BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report® GlobeNewswire +25.42%
Feb-02-21 08:30AM	NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimers Trial GlobeNewswire +5.31%
Oct-30-20 08:00AM	BioVie Interview to Air on Bloomberg International on the RedChip Money Report GlobeNewswire
Oct-29-20 08:00AM	BioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020 GlobeNewswire
Sep-23-20 08:00AM	BioVie Announces Closing of Public Offering of Common Stock GlobeNewswire
Sep-21-20 07:00AM	BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit ACCESSWIRE
Sep-17-20 07:55PM	BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering ACCESSWIRE -20.38%
Jun-16-20 08:30AM	Highly Accomplished Executives Join BioVies Board of Directors GlobeNewswire
Jun-11-20 08:30AM	BioVie Advances the BIV201 Clinical Program and Prefilled Syringe GlobeNewswire
Dec-09-19 08:00AM	BioVie Manufactures Novel Terlipressin Prefilled Syringe GlobeNewswire
Oct-22-19 07:00AM	BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA ACCESSWIRE +20.00%

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORLIN STEVE	Director	Nov 03	Buy	7.95	2,430	19,318	45,100	Dec 15 03:01 PM
GORLIN STEVE	Director	Oct 30	Buy	7.97	2,570	20,483	42,670	Dec 15 03:00 PM
GORLIN STEVE	Director	Oct 21	Buy	9.19	5,000	45,950	40,100	Oct 22 03:10 PM
GORLIN STEVE	Director	Oct 15	Buy	10.19	5,100	51,967	25,100	Oct 19 02:59 PM
GORLIN STEVE	Director	Oct 15	Buy	10.05	10,000	100,550	35,100	Oct 19 02:59 PM
GORLIN STEVE	Director	Oct 09	Buy	9.61	282	2,710	20,000	Oct 14 02:07 PM
GORLIN STEVE	Director	Oct 07	Buy	9.42	4,718	44,444	19,718	Oct 14 02:05 PM
GORLIN STEVE	Director	Sep 22	Buy	10.00	15,000	150,000	15,000	Oct 14 01:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience